SG11201400215SA - Use of the pacap as a molecular adjuvant for vaccines - Google Patents

Use of the pacap as a molecular adjuvant for vaccines

Info

Publication number
SG11201400215SA
SG11201400215SA SG11201400215SA SG11201400215SA SG11201400215SA SG 11201400215S A SG11201400215S A SG 11201400215SA SG 11201400215S A SG11201400215S A SG 11201400215SA SG 11201400215S A SG11201400215S A SG 11201400215SA SG 11201400215S A SG11201400215S A SG 11201400215SA
Authority
SG
Singapore
Prior art keywords
pacap
vaccines
molecular adjuvant
adjuvant
molecular
Prior art date
Application number
SG11201400215SA
Other languages
English (en)
Inventor
González Juana María Lugo
González Yamila Carpio
García Mario Pablo Estrada
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of SG11201400215SA publication Critical patent/SG11201400215SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201400215SA 2011-08-26 2012-08-24 Use of the pacap as a molecular adjuvant for vaccines SG11201400215SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2011000167A CU24075B1 (es) 2011-08-26 2011-08-26 Composición vacunal que comprende el péptido activador de la adenilato ciclasa de pituitaria como adyuvante molecular.
PCT/CU2012/000004 WO2013029570A1 (es) 2011-08-26 2012-08-24 Uso del pacap como adyuvante molecular para vacunas

Publications (1)

Publication Number Publication Date
SG11201400215SA true SG11201400215SA (en) 2014-09-26

Family

ID=47046313

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400215SA SG11201400215SA (en) 2011-08-26 2012-08-24 Use of the pacap as a molecular adjuvant for vaccines

Country Status (20)

Country Link
US (1) US9549977B2 (enExample)
EP (1) EP2749291B1 (enExample)
JP (1) JP6077541B2 (enExample)
KR (1) KR101857705B1 (enExample)
CN (1) CN103874510A (enExample)
AU (1) AU2012303887B2 (enExample)
BR (1) BR112014004620B1 (enExample)
CA (1) CA2844898C (enExample)
CL (1) CL2014000386A1 (enExample)
CU (1) CU24075B1 (enExample)
ES (1) ES2648337T3 (enExample)
MX (1) MX351725B (enExample)
MY (1) MY191697A (enExample)
NO (1) NO2749291T3 (enExample)
PH (1) PH12014500397B1 (enExample)
PT (1) PT2749291T (enExample)
RU (1) RU2580294C2 (enExample)
SG (1) SG11201400215SA (enExample)
WO (1) WO2013029570A1 (enExample)
ZA (1) ZA201401271B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190060057A (ko) 2017-11-24 2019-06-03 유병희 웰빙 무드등
WO2020230869A1 (ja) * 2019-05-14 2020-11-19 千寿製薬株式会社 Pacapペプチド又はpacapの安定化ペプチドを含む神経栄養性角膜炎の予防又は治療用組成物
CN117617183B (zh) * 2023-11-29 2025-09-05 中国医学科学院医药生物技术研究所 突变体斑马鱼在制备凝血功能障碍疾病的动物模型中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE65568B1 (en) * 1990-10-22 1995-11-01 Unilever Plc Vaccine compositions for fish
DE60039111D1 (de) * 1999-09-28 2008-07-17 Bayer Corp Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung
GB0427267D0 (en) * 2004-12-13 2005-01-12 Maria Teresa De Magistris Peptide adjuvants
CU23557A1 (es) 2005-11-22 2010-07-20 Ct Ingenieria Genetica Biotech Neuropéptidos para el cultivo de organismos acuáticos
JP5908406B2 (ja) * 2009-11-02 2016-04-26 ジ アドミニストレーターズ オブ ザ トゥレーン エデュケーショナル ファンド 下垂体アデニル酸シクラーゼ活性化ポリペプチド(pacap)の類似体およびその使用方法
CN103255089B (zh) * 2013-05-03 2015-08-05 中国水产科学研究院黄海水产研究所 一株强毒迟缓爱德华氏菌疫苗株及其应用

Also Published As

Publication number Publication date
AU2012303887A1 (en) 2014-03-06
WO2013029570A1 (es) 2013-03-07
MX2014002214A (es) 2014-04-30
RU2014111465A (ru) 2015-10-10
KR20140064847A (ko) 2014-05-28
BR112014004620A2 (pt) 2017-03-21
JP2014524450A (ja) 2014-09-22
BR112014004620B1 (pt) 2019-10-29
PH12014500397B1 (en) 2018-09-12
CN103874510A (zh) 2014-06-18
CU20110167A7 (es) 2013-06-28
RU2580294C2 (ru) 2016-04-10
NO2749291T3 (enExample) 2018-03-17
CA2844898C (en) 2021-06-22
MY191697A (en) 2022-07-07
PH12014500397A1 (en) 2014-04-14
KR101857705B1 (ko) 2018-06-20
CL2014000386A1 (es) 2014-07-11
EP2749291B1 (en) 2017-10-18
EP2749291A1 (en) 2014-07-02
ZA201401271B (en) 2015-04-29
JP6077541B2 (ja) 2017-02-08
US20140294889A1 (en) 2014-10-02
PT2749291T (pt) 2017-11-24
ES2648337T3 (es) 2018-01-02
CA2844898A1 (en) 2013-03-07
US9549977B2 (en) 2017-01-24
MX351725B (es) 2017-10-25
AU2012303887B2 (en) 2017-06-22
CU24075B1 (es) 2015-01-29

Similar Documents

Publication Publication Date Title
ZA201401012B (en) Parenteral novovirus vaccine formulations
IL231951A0 (en) Excipients and their use for the preparation of preparations
IL233217A0 (en) Anti-human papillomavirus compounds
EP2678005A4 (en) GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
ZA201109164B (en) Vaccine
IL231043A0 (en) vaccine
ZA201402071B (en) Vaccine therapy
GB201119999D0 (en) Vaccine
GB201014965D0 (en) Vaccine
ZA201306245B (en) Combination vaccines
ZA201401271B (en) Use of the pacap as a molecular adjuvant for vaccines
ZA201404512B (en) Malaria vaccine
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
GB201120000D0 (en) Vaccine
IL225413A0 (en) Vaccination
GB201109294D0 (en) Novel vaccine
GB201108982D0 (en) Vaccines
GB201108984D0 (en) Vaccines
GB201108986D0 (en) Vaccines
GB201121647D0 (en) Vaccine
GB201108256D0 (en) Vaccine
AU2011900262A0 (en) Combination vaccines
AU2011900657A0 (en) Vaccine
GB201009277D0 (en) Novel vaccine